- #70 B Parthasaradhi Reddy & family ₹39,400 Cr

About Hetero Biopharma Limited
Data last updated:
Hetero Biopharma Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Hetero Labs Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 September 2016 and has been in existence for over 10 years.
Its director B Parthasaradhi Reddy and family are #70 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24290TG2016PLC111946. Its GSTIN is 36AADCH9806P1ZY (Telangana). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹207 Cr and a paid-up capital of ₹150.05 Cr. It was formerly known as Hetero Biopharma Ltd. It is led by directors including Bandi Vamsikrishna and Govindaraju Bhavani.
Its last annual general meeting (AGM) was held on 28 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.
As per the financials filed for FY 2026, the company reported a revenue of ₹525.07 Cr, a growth of 31% compared to the previous year. For the same year it recorded a net profit of ₹33.5 Cr (net margin 6.4%) and EBITDA of ₹119.5 Cr (EBITDA margin 22.8%). Revenue has grown at a compounded annual rate (CAGR) of 15% over three years and 32% over five years.
The company has about 444 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 2 brands: Hetero Biopharma and Hetero. As per MCA filings, the company has open charges of ₹252.15 Cr on record. Court records list 2 cases involving the company, including 2 filed against it; 1 case is pending. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹150 Cr; the latest was in March 2019. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 212 overdue payments to 31 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hetero.com.
Company details
Recognitions & Rankings of Hetero Biopharma
Contact details
Hetero Biopharma Limited's registered office is in Hyderabad, Telangana. Its website is hetero.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address#7 – 2 – A2 Industrial Estate, Sanath Nagar, Hyderabad, Telangana, India – 500018
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Hetero Biopharma Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Hetero Biopharma operates two associated brands: Hetero Biopharma and Hetero. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Development and manufacturing of biosimilars and biopharmaceuticals are conducted by Hetero Biopharma in the healthcare sector. | heterobiopharma.com | |
| Hetero is recognized as a leading global pharmaceutical company based in India. | hetero.com |
Business activity
The main business activity of Hetero Biopharma is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Hetero Biopharma Limited, buy the company report.
Financials of Hetero Biopharma Limited
FY 2026 filings availableHetero Biopharma Limited reported revenue of ₹525.07 Cr (up 31% YoY) for FY 2026.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 32% over five years, including 31% growth in the latest year. EBITDA rose 19% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹525.07 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹119.5 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹33.5 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 22.8% | ||||
| Net Profit Margin | 6.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Hetero Biopharma Limited, buy the company report.
Board of directors of Hetero Biopharma Limited
Hetero Biopharma has 4 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bandi Vamsikrishna Also directs: Allita Finvest and Advisors LLP, Eliana Investments and Holdings LLP, Krishn Capital Advisors LLP and 5 more | Director | 25 Mar 2021 | 5 Years 7 Months | Current |
| Govindaraju Bhavani Also directs: Hetero Labs Limited, Annora Pharma Private Limited | Director | 26 Aug 2022 | 4 Years 2 Months | Current |
| Parthasaradhi Reddy Bandi Also directs: Allita Finvest and Advisors LLP, Eliana Investments and Holdings LLP, Krishn Capital Advisors LLP and 5 more | Director | 14 Sep 2016 | 10 Years 2 Months | Current |
| Bhaskarreddy Pabbatireddy | Additional Director | 26 Sep 2025 | 1 Years 1 Months | Current |
Auditor
Hetero Biopharma Limited is audited by M V Narayana Reddy & Co for the financial year 2026.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M V Narayana Reddy & Co | FY 2026 | 002370S |
Shareholding
The shareholding of Hetero Biopharma Limited is on record for 5 financial years, the latest being FY 2026, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Hetero Biopharma Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Mar 2025 | 101078891 | Sbicap Trustee Company Limited | ₹75 Cr | Open | |
| 27 Mar 2025 | 101077053 | Sbicap Trustee Company Limited | ₹83 Cr | Open | |
| 14 Feb 2024 | 100890394 | Others | ₹25 Lakh | Open | |
| 20 Feb 2023 | 100687093 | Others | ₹20 Lakh | Open | |
| 07 Jun 2022 | 100607618 | Others | ₹97.93 Lakh | Open |
To see the full charge records of Hetero Biopharma Limited, buy the company report.
Total charge records: 6 View all charges
Deals & funding
Hetero Biopharma Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹150 Cr; the latest was in March 2019.
Deals on record (1 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2017 | Secondary share transfer | Undisclosed | Buyer: Hetero Labs Limited & Mohan Reddy Chilukuri Seller: Hetero Labs Limited & Chandra Sekhar Tummuluru |
To see the full deal history of Hetero Biopharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Hetero Biopharma Limited has 2 court cases on record: 2 filed against it. 1 case is pending and 1 is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 2 | 1 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, MAHARASHTRA | Petition | Filed against the company by Roche Products India Pvt Ltd and 1 other | Pending |
| High Court, MAHARASHTRA | Court case (COMIP) | Filed against the company by Genentech Inc and Anr | Disposed |
To see the full case history of Hetero Biopharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Hetero Biopharma Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 212 overdue payments to 31 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 31)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Nicomac Taikisha Clean Rooms Private Limited | |||
| an individual supplier | |||
| Devson Impex Private Limited | |||
| LCGC Chrom Consumables LLP | |||
| PJB Projects Private Limited |
To see the full MSME payment records of Hetero Biopharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Hetero Biopharma has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Hetero Plasma Sciences Private Limited | U46497TS2023PTC175917 |
To see the full group structure of Hetero Biopharma Limited, buy the company report.
Employees & EPFO
Hetero Biopharma Limited has a workforce of 444 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 444 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 |
To see the full employee and EPFO history of Hetero Biopharma Limited, buy the company report.
GST
Hetero Biopharma has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCH9806P1ZY | Telangana | Active | 01 Jul 2017 |
| 36AADCH9806P2ZX | Telangana | Active | 06 Jul 2017 |
To see the full GST registrations and return filing status of Hetero Biopharma Limited, buy the company report.
Recent activity
Hetero Biopharma Limited has 13 board changes on record since 2016: 6 appointments and 7 cessations. The latest: Bhaskarreddy Pabbatireddy was appointed as Additional Director on 26 Sep 2025.
11 earlier events are in the company report.
News
Frequently asked questions
Hetero Biopharma is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 14 September 2016 (10+ years old) and is registered under CIN U24290TG2016PLC111946.
Hetero Biopharma has 4 current directors:
- Bandi Vamsikrishna - Director
- Govindaraju Bhavani - Director
- Parthasaradhi Reddy Bandi - Director
- Bhaskarreddy Pabbatireddy - Additional Director
The latest financial statements of Hetero Biopharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 28 August 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Hetero Biopharma is 36AADCH9806P1ZY, registered in Telangana. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AADCH9806P2ZX (Telangana).
The CIN (Corporate Identification Number) of Hetero Biopharma is U24290TG2016PLC111946. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Hetero Biopharma has 2 court cases on record: 2 filed against it. 1 is pending.
Hetero Biopharma was incorporated on 14 September 2016, making it 10+ years old. It is registered with the Registrar of Companies, Hyderabad.
Hetero Biopharma has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹150 Cr; the latest was in March 2019.
Bhaskarreddy Pabbatireddy was appointed as Additional Director on 26 Sep 2025. Bhavesh Bansidhar Pujara ceased to be Additional Director on 18 Sep 2024. Bhavesh Bansidhar Pujara was appointed as Director on 14 Jun 2024. Hetero Biopharma has 13 board changes on record in total.
Hetero Biopharma has 14 MSME Form 1 returns on record between 2019 and 2024, listing 212 overdue payments to 31 micro and small suppliers. The latest return was filed on 30 Apr 2024.
Hetero Biopharma can be reached through the website hetero.com. Its registered office is in Hyderabad, Telangana, India.

